---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-012446"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2023-02-16T23:59:59+00:00"
generated_at: "2026-06-19T09:40:14.598073+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Jasper Therapeutics reports positive briquilimab data: 3 SCD patients achieve 100% donor chimerism

## Summary
- First two sickle cell disease patients achieved 100% donor myeloid chimerism at Day 100; third at Day 30.
- All three patients increased hemoglobin at last follow-up (to 11.4–14 g/dL from baseline 8–10 g/dL).
- No graft-versus-host disease or briquilimab-related severe adverse events observed.
- Data presented in plenary session at 2023 Tandem Meetings (ASTCT/CIBMTR) on novel antibody-based conditioning.
- Study is Phase 1/2 (NCT05357482) evaluating briquilimab as conditioning for bone marrow transplant in SCD and beta thalassemia.

## SEC filing metadata
- accession: 0001213900-23-012446
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2023-02-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390023012446/0001213900-23-012446-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390023012446/ea173843-8k_jasper.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-012446
- JSON: https://secwatch.observer/filing/0001213900-23-012446.json
- Plain text: https://secwatch.observer/filing/0001213900-23-012446.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.